S-1/A: Farlong Holding Files S-1/A for IPO Amid Going Concern Doubt

Farlong Holding Corporation filed an S-1/A for its initial public offering of 4,000,000 shares at an estimated $4.00 per share, while acknowledging significant accumulated deficits and recurring losses raising substantial doubt about its ability to continue as a going concern.

Summary

• Farlong Holding Corporation is pursuing an Initial Public Offering (IPO) of 4,000,000 shares of common stock at an estimated price of $4.00 per share, with an option for underwriters to purchase an additional 600,000 shares.
• The company aims to list its common stock on the Nasdaq Capital Market under the symbol AFA, with listing approval being a condition for the offering's closing.
• Net proceeds from the IPO are estimated at approximately $14.5 million (or $16.6 million if the over-allotment option is fully exercised), intended for general corporate purposes, R&D, marketing, infrastructure upgrades, and international expansion.
• Farlong is a science-driven healthcare and wellness company focused on proprietary herbal supplements and its DirecTCM platform, which was officially launched in May 2025.
• As of December 31, 2025, the DirecTCM platform had approximately 30,000 pre-registered healthcare providers, with 108 active users (0.36% of pre-registered).
• The company has experienced recurring net losses and negative cash flows from operating activities since 2022, with an accumulated deficit of $7,339,948 as of December 31, 2025.
• Management has explicitly stated that these financial conditions raise substantial doubt about the company's ability to continue as a going concern.
• Karin Mei Huang, through KML Family Trust and KMA Trust, will hold 90.9% of the aggregate voting power of the company's common stock immediately after the IPO, making Farlong a controlled company.
• The company relies heavily on third-party contract manufacturers located in China for all its supplement products, exposing it to significant risks from U.S. tariffs and trade disputes.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with low sentiment due to significant ongoing losses, negative cash flow, and explicit 'going concern' doubt, despite the IPO attempt and some positive operational developments. The high dilution for new investors and reliance on related-party financing further weigh on the outlook.

Positives

• The DirecTCM platform, launched in May 2025, has accumulated approximately 30,000 pre-registered healthcare providers, indicating potential for future growth in its B2B channel.
• Revenue for the three months ended December 31, 2025, increased by 24.77% to approximately $0.2 million compared to the same period in 2024.
• Gross profit for the three months ended December 31, 2025, increased by 58.99% to $143,164, with the gross margin improving to 77.12% from 60.52% in the prior year period.
• The BioPrecision formulation product line, a strategic focus, generated approximately $65,152 in revenue for the three months ended December 31, 2025, an increase of 17.17% year-over-year.
• The company has achieved self-affirmed GRAS (Generally Recognized As Safe) conclusions for several principal botanical ingredients used in its BioPrecision supplements, enhancing product credibility.
• Ongoing preclinical research studies are being conducted with City of Hope for White Button Mushroom, Polygonum Capitatum, and Rodgersia Sambucifolia Hemsl. extracts, demonstrating a commitment to scientific validation.
• Cornerstone investors, ACA Care Management, LLC and Epiphron Capital (Hong Kong) Limited, have indicated interest in purchasing up to $5 million in shares in this offering, showing some investor confidence.
• The company has an experienced management team, including CFO Chiwen Claire Wang, with a strong background in financial management and public company auditing.

Negatives

• The company has an accumulated deficit of $7,339,948 as of December 31, 2025, and has experienced recurring net losses from operations and negative cash flows since 2022.
• Management has determined that these conditions raise substantial doubt about the company's ability to continue as a going concern.
• Net loss for the three months ended December 31, 2025, increased by 73.73% to $700,240, compared to $403,059 for the same period in 2024.
• Total revenue for the fiscal year ended September 30, 2025, decreased by 5.19% to $0.7 million compared to $0.8 million in the fiscal year ended September 30, 2024.
• Average revenue per retail customer decreased by 59.85% to approximately $700 for the three months ended December 31, 2025, indicating a shift towards smaller-quantity purchases.
• The company relies on a small number of customers and vendors, with significant concentration risks; for example, three vendors accounted for 73%, 16%, and 11% of total purchases for Q4 2025.
• A significant portion of revenue is derived from sales on Amazon and TikTok (27% and 4% respectively for Q4 2025), making the business vulnerable to platform policy changes or restrictions.
• Past clinical studies for Notoginseng, InnerPure, and Breviscapine did not demonstrate statistically significant outcomes, which may diminish consumer confidence in product efficacy claims.
• New investors in the IPO will experience immediate and substantial dilution of $3.75 per share.
• Material weaknesses in internal control over financial reporting have been identified, including a lack of formal policies for risk assessment and IT-related deficiencies.
• The former Chief Executive Officer, Jackson Kwok, resigned in December 2025 due to personal health issues, and the company is currently seeking a permanent CEO, creating leadership uncertainty.
• The company is highly vulnerable to U.S. tariffs, trade disputes, and other disruptions related to U.S.-China trade relations due to its reliance on Chinese contract manufacturers for all supplement products.

Risks

• Significant accumulated deficits and recurring losses raise substantial doubt about the ability to continue as a going concern.
• Additional capital may be needed and may not be available on commercially acceptable terms, if at all.
• Operating results may vary considerably in the future, making forecasting challenging and potentially causing results to fall short of expectations.
• Failure to maintain high-quality standards for products and services could harm the business and damage reputation.
• Reliance on a small number of customers and vendors; loss of any material customer or vendor could adversely affect results of operations.
• Customer demand is difficult to forecast accurately, potentially leading to an inability to match planning and spending decisions.
• Any limitation or restriction on selling products on Amazon and TikTok platforms could have a material adverse impact.
• Increases in ingredient costs, long lead times, supply shortages, and changes could disrupt the supply chain and negatively impact financial results.
• Allocation of limited resources to particular products or services may lead to failure to capitalize on more profitable opportunities.
• Risk of inventory spoliation due to definitive shelf-lives, potentially leading to significant write-offs.
• Failure to renew current leases or locate desirable alternatives for facilities could materially and adversely affect the business.
• Future need for licenses for third-party technology that could be unavailable or offered on commercially unreasonable terms.
• High costs and uncertainty of litigation may prevent enforcement of intellectual property rights against third parties.
• Struggles to partner with others for technological advancements and new products and services.
• Use of open-source software could subject proprietary software to general release, hinder product sales, and expose the company to potential litigation.
• Exposure to risks associated with credit card and other online payment chargebacks and fraud.
• Risks associated with the return policy and warranty if actual returns or warranty claims exceed estimates.
• Clinical studies present inherent risks, and past results have not demonstrated statistical significance, potentially diminishing consumer confidence.
• Failure to maintain, protect, or enhance brands (Dr. Herbal Well, Best Doctor Formula) could materially and adversely affect the business.
• Sourcing ingredients from foreign suppliers (primarily China) exposes the company to international trade and importation risks, including U.S. tariffs and trade disputes.
• Substantial portion of sales relies on distributors and health professionals, over whom the company has limited control.
• Reliance on independent third-party transportation providers for product shipments, subject to increased costs and potential inability to deliver on a timely basis.
• Insurance does not fully cover all operational risks, and changes in cost or availability could increase costs or result in decreased coverage.
• Disruptions in data and information systems (including third-party providers) could harm reputation and ability to run the business.
• Failure to protect intellectual property rights could adversely affect the business.
• Third parties may claim infringement of their proprietary intellectual property rights, leading to significant legal expenses and preventing product promotion.
• Inability to protect the confidentiality of trade secrets and know-how could harm competitive position.
• Inadequate protection of trademarks and trade names may hinder name recognition and adversely affect the business.
• Business is subject to risks from natural and manmade catastrophic events.
• Recent changes to the board of directors and management (Interim CEO) may create uncertainty and affect the ability to attract or retain key personnel.
• Cybersecurity risks could adversely affect the business and disrupt operations, including a recent incident at an underwriter.
• Reliance heavily on third parties for computing, storage, processing, and related services; any disruption could negatively impact the business.
• Future acquisitions may have an adverse effect on the ability to manage the business.
• Competition in the herbal supplement industry may decrease net revenue.
• Global economic conditions could materially and adversely affect the company's business, financial condition, results of operations, and growth.
• Risk of intellectual property litigation, with claims of infringement against the company potentially hurting the business.
• Subject to numerous laws and regulations applicable to the herbal supplement industry; violations may materially and adversely affect the business.
• Changes in FDA and other regulatory agency policies, or disagreements over product classifications, could delay or increase costs of offering products.
• Compliance with laws and regulations related to the manufacture, sale, and marketing of herbal supplements can increase costs, limit sales, and expose to enforcement actions.
• Economic downturns or a change in consumer preferences, perception, and spending habits could limit consumer demand for products.
• Marketing activities for products are subject to strict governmental regulation, which may limit ability to market or promote.
• Failure to comply with federal, state, and foreign laws and regulations relating to privacy, data protection, and consumer protection could result in significant liability.
• May be the subject of allegations, harassment, or other detrimental conduct by third parties, which could harm reputation and cause loss of market share and customers.
• No public market for common stock prior to this offering; may not be able to resell at or above the IPO price, or at all.
• The market price of common stock may be volatile or may decline regardless of operating performance.
• The price of common stock could be subject to rapid and substantial volatility due to relatively small public float.
• Immediate and substantial dilution in the net tangible book value of common stock purchased in this offering.
• Failure to implement and maintain an effective system of internal controls or remediate identified material weaknesses.
• Substantial increased costs as a result of being a public company.
• Inability to continue to satisfy Nasdaq listing requirements could lead to delisting.
• If securities or industry analysts do not publish research or reports about the business, or if they publish a negative report, the price of common stock and trading volume could decline.
• Management has broad discretion to determine how to use the funds raised in the offering.
• As a controlled company, the company is allowed to follow certain exemptions from corporate governance requirements that could adversely affect public stockholders.
• Anti-takeover provisions in Articles of Incorporation and Bylaws, as well as Nevada law, might discourage, delay, or prevent a change in control.
• The sale of a significant number of shares after lock-up expiration may cause the market price of common stock to drop significantly.
• As an emerging growth company and a smaller reporting company, reduced disclosure requirements may make common stock less attractive to investors.
• Nasdaq may apply additional and more stringent criteria for initial and continued listing due to a relatively small public offering and large insider holdings.
• Preferred stock is authorized and can be designated by the board without stockholder approval, potentially causing substantial dilution or affecting voting rights.

Future Outlook

The company plans to use the net proceeds from the IPO to expand its DirecTCM platform and product offerings, including widening product availability through major e-commerce platforms and retail partnerships. Significant investment is planned for technology and R&D, including refining BioPrecision products, pursuing self-affirmed GRAS conclusions for additional extracts, and funding pilot production of next-generation WBM REx products. The company also intends to finance marketing and operational expenses for direct-to-consumer channel growth, physician outreach, and market expansion, including hiring eight field sales representatives and launching educational roadshows. International expansion to Asian and European markets for the DirecTCM platform is also a key strategic objective.

Management Comments

• "We are currently seeking a permanent Chief Executive Officer."
• "We believe Mr. Cheng is well qualified to serve as our director because of his financial management experience and deep understanding of the Company’s operations gained through his role as accounting controller."
• "We believe Ms. Wang is well qualified to serve as our director since she brings a distinguished background in financial management and strategic leadership."
• "We believe our future success depends on our ability to maintain and grow the value of our brands, Dr. Herbal Well and Best Doctor Formula."
• "We believe we have sufficient substantiation for all material advertising claims for our products in the United States and have organized our documentation accordingly."
• "We believe that its income tax filing positions and deductions will be sustained on audit and do not anticipate any adjustments that will result in a material change to its financial position."

Industry Context

StockSavvy.ai notes that Farlong operates in a rapidly expanding global dietary supplement market, valued at $74.3 billion in 2024 and projected to reach $170.1 billion by 2034 (9.5% CAGR). The holistic herbal supplement market specifically is also growing, from $216 billion in 2022 to an expected $421 billion by 2032 (6.87% CAGR). The company's focus on science-driven, plant-based formulations and its DirecTCM platform aligns with increasing consumer demand for natural, clinically-backed wellness solutions and personalized health approaches. However, the industry is highly competitive, with many larger, more resourced players, and is subject to evolving regulatory scrutiny, particularly regarding product claims and classifications.

Comparison to Industry Standards

• Farlong's gross margin of 77.12% for Q4 2025 is strong, but the BioPrecision line's lower margin of 30.48% for FY 2025 suggests a market entry strategy that prioritizes volume or market share over immediate profitability for this key product line. This contrasts with established players like Herbalife Nutrition or GNC, which typically aim for higher margins across their core product portfolios once market presence is solidified.
• The company's recurring net losses and 'going concern' doubt are significantly below industry standards for stable, publicly traded companies, indicating a high-risk profile compared to profitable competitors.
• The reliance on a small number of Chinese contract manufacturers and major e-commerce platforms like Amazon and TikTok presents a concentration risk that is higher than diversified industry leaders who often have broader supply chains and multiple sales channels to mitigate such dependencies.
• The lack of statistically significant outcomes in past clinical studies for products like Notoginseng, InnerPure, and Breviscapine, while common for exploratory dietary supplement studies, falls short of the robust, statistically significant evidence typically sought by consumers and healthcare professionals for premium, science-backed products, potentially limiting competitive differentiation against companies with stronger clinical validation.

Management Changes

Corporate Governance

Legal Proceedings

• A lawsuit was filed on June 20, 2024, against Longstar and several other entities by a former employee, alleging $1,222,000 in unpaid compensation from 2016 to 2023. Longstar maintains that all wages were paid, and its legal counsel has concluded that the likelihood of liability is remote, so no loss contingency has been recorded.

Related Party Transactions

• Rent deposit of $19,500 owed to Longstar Healthpro Manufacturing Inc., which is majority-owned by Xinjiang Lixing, a former stockholder of Longstar.
• Rent expenses paid to Longstar Healthpro Manufacturing Inc. were $40,950 for the three months ended December 31, 2025, and $156,650 for the fiscal year ended September 30, 2025.
• Accounts payable to Yunnan Panlong Yunhai Pharmaceutical Co., Ltd. of $60,441 as of December 31, 2025, where Ms. Lihua Zeng (sister of Lipin Zeng, a trustee of a major stockholder trust) owns 30% ownership interests.
• Accounts payable to Yunnan Panlong Yunhai Pharmaceutical Trading Co., Ltd. of $32,980 as of December 31, 2025, which is a wholly-owned subsidiary of Yunnan Panlong Yunhai Pharmaceutical Co., Ltd.
• Accounts payable to Kunming Aoqun Bio-Tech Co., Ltd. of $781,668 as of December 31, 2025, where Ms. Lihua Zeng serves as a director.
• Accrued loan interest of $240,884 as of December 31, 2025, owed to Karin Mei Huang, the former sole stockholder of Longstar and current trustee of major stockholder trusts.
• Long-term loans from Karin Mei Huang totaling $4,600,000 as of December 31, 2025, with an annual interest rate of 9.5% and maturity dates ranging from September 15, 2029, to September 26, 2030.
• Purchases from Kunming Aoqun Bio-Tech Co., Ltd. amounted to $131,148 for the fiscal year ended September 30, 2025, and $815,172 for the fiscal year ended September 30, 2024.
• Purchases from Yunnan Panlong Yunhai Pharmaceutical Trading Co., Ltd. amounted to $4,324 for the three months ended December 31, 2025, and $23,390 for the fiscal year ended September 30, 2025.
• A Share-for-Share Exchange on December 27, 2023, resulted in Karin Mei Huang exchanging all her Longstar shares for 40,000,000 shares of Farlong's common stock, making Farlong the parent company.
• An Asset Transfer Agreement on December 31, 2022, involved Longstar repurchasing shares from Xinjiang Lixing (under common control of Karin Mei Huang) by transferring real property, ACA common stock, and other assets.
• On January 31, 2025, Karin Mei Huang transferred her 40,000,000 Farlong common stock shares to KML Family Trust (80%) and KMA Trust (20%) for estate planning purposes.

Stakeholder Impact

• Shareholders: New investors face immediate and substantial dilution of $3.75 per share. Existing shareholders (Karin Mei Huang and family trusts) will retain significant control (90.9% voting power). The 'going concern' doubt poses a high risk of loss of investment for all shareholders.
• Employees: Management changes, including an interim CEO and former CTO resignation, could create uncertainty. The company's growth strategies and R&D investments aim to attract and retain qualified personnel, but financial instability could impact employee morale and retention.
• Customers: Expansion of the DirecTCM platform and product lines aims to enhance customer experience and access to products. However, potential quality issues, supply chain disruptions, or regulatory non-compliance could negatively impact customer trust and demand.
• Suppliers: Reliance on a few significant suppliers, particularly in China, exposes the company to risks from trade disputes, tariffs, and operational disruptions, potentially affecting product availability and costs, which could strain supplier relationships.
• Creditors: The company's recurring losses and 'going concern' doubt increase credit risk, potentially making future debt financing more difficult or expensive. Related-party loans are a significant source of financing, indicating a reliance on insider capital.

Next Steps

• Complete the initial public offering and list common stock on Nasdaq under the symbol AFA.
• Utilize net proceeds for general corporate purposes, R&D, marketing, infrastructure upgrades, and international expansion.
• Continue preclinical research studies with City of Hope on White Button Mushroom, Polygonum Capitatum, and Rodgersia Sambucifolia Hemsl. extracts.
• Refine newly developed products, including self-affirmed GRAS dossiers for two additional extracts, and fund pilot production of next-generation BioPrecision products (WBM REx).
• Hire eight field sales representatives and launch three educational roadshows within the next 15 months to finance marketing and operational expenses.
• Upgrade the DirecTCM platform, including hiring more internal software engineers and increasing Amazon Web Services and cloud storage capacity within 24 months.
• Expand DirecTCM platform service to Asian and European markets, which is expected to require approximately $2 million of additional capital for full commercial rollout.
• Identify and hire a permanent Chief Executive Officer following the interim appointment of Simon Cheng.
• Implement additional remedial measures for identified material weaknesses in internal control over financial reporting, including hiring qualified accounting personnel and implementing U.S. GAAP/SEC reporting training programs.
• Implement a policy prohibiting hedging transactions by employees and officers in the future.
• Form an Audit Committee and Compensation Committee upon the effectiveness of the registration statement to enhance corporate governance.

Key Dates

Recommendation

The filing reveals a company in a precarious financial state, explicitly stating 'substantial doubt about our ability to continue as a going concern' due to recurring losses and negative cash flows. While an IPO is planned, the immediate and substantial dilution for new investors, coupled with significant reliance on related-party financing and manufacturing in a high-risk geopolitical region (China), presents a highly unfavorable risk-reward profile. The lack of statistically significant clinical trial outcomes for key products further undermines the 'science-driven' claim. Given these severe financial and operational challenges, a seasoned investor would likely recommend a strong sell, as the risks far outweigh any potential upside from the IPO or growth strategies.

Keywords

Herbal supplements, Dietary supplements, IPO, Farlong Holding Corporation, DirecTCM, Traditional Chinese Medicine, Health and wellness, BioPrecision, GRAS, Nasdaq, S-1/A, Preclinical studies, Corporate governance, Risk factors, Financial reporting, U.S.-China trade, E-commerce, Amazon, TikTok, Going concern, Dilution